Learn more
Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Request a Rep Referral Form
Skip to main content
Referral Form

ABOUT PH-ILD

CLINICAL STUDIES

WHAT IS TYVASO?

DOSING & DEVICES

RESOURCES & SUPPORT

PATIENT STORIES

Site map

HOME

ABOUT PH-ILD

Pathophysiology

Prevalence

Early PH Detection

Routine ILD Tests

The Role of Echo

Diagnosing PH-ILD

CLINICAL STUDIES

INCREASE/INCREASE OLE Study Design

INCREASE/INCREASE OLE Efficacy

INCREASE Safety

BREEZE Study

WHAT IS TYVASO?

Direct to Lungs

FAQs

DOSING & DEVICES

TYVASO DPI

TYVASO Nebulizer

Dosing & Titration

Reaching Target Dose

RESOURCES & SUPPORT

Getting Started

Managing AEs

Patient Support

HCP Support

Resource Library

PATIENT STORIES

Patient Stories

REQUEST A REP

PRESCRIBING INFORMATION

TYVASO

TYVASO DPI

INSTRUCTIONS FOR USE

TYVASO

TYVASO DPI

REFERRAL FORM

PATIENT SITE

AE=adverse event; DPI=dry powder inhaler.

The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.

CLOSE

Yes, I am a US healthcare professional and would like to continue.